Two reports out from FirstView are shedding light on the way market barriers - factors unrelated to safety and efficacy - affect the way rheumatologists prescribe rheumatoid arthritis (RA) treatments in the US and the EU5 countries (France, Germany, Italy, Spain and the UK).
Market barriers include factors such as, cost, market access, patient preferences, guidelines and recommendations, and more. FirstView's Market Access Impact: Rheumatoid Arthritis 2017 reports for the US and EU5 examine the effects of seven such barriers on Actemra/RoActemra, Cimzia, Enbrel, Humira, Inflectra, Rituxan/MabThera, Orencia, Remicade, Simponi and Xeljanz. The US reports also includes Kevzara, and the EU5 report also includes Benepali and Remsima. Both reports are based on surveys with practicing rheumatologists.
In the US and EU5, prescribing rates for RA treatments are high despite the challenges of market barriers. In the US, over 80 percent or more of the doctors surveyed prescribe nine of the 11 brands covered, and 100 percent prescribe the top brand.
While the numbers aren't as high in Europe, where over 60 percent or more of the doctors surveyed prescribe nine of the 12 brands covered, and only 90 percent prescribe the top brand, prescribing rates are healthy.
Another area where there are differences is in the impact of biosimilars. In Europe, biosimilars are beginning to have an impact, with the most prescribed biosimilar gaining the most share overall. In the US, however, biosimilars are struggling to gain traction. The most prescribed biosimilar is prescribed by just over a third of physicians, but removing barriers could double that.
Moreover, the US and Europe differ on issues such as brand awareness and where the impact of eliminating barriers would be most acutely felt. For example, in the US, surveyed doctors have good awareness of all surveyed brands, but in Europe three brands have perception problems, with just over 20 percent of doctors surveyed saying they would not consider prescribing those brands.
Full reports available from FirstView
These and many other insights, along with the full survey results are available from the FirstView web site, saving companies the time and expense of commissioning bespoke research from external agencies.
Or contact FirstView for more information by calling +1 212-220-0880 or +44(0)20.7665.9240
To read more Analyst Notes articles, click here.